NASDAQ OMX

Scientific breakthrough on objective diagnosis of PTSD

Dela
  • Scientific breakthrough for non-invasive, automatic, objective diagnosis of PTSD leveraging autonomic biomarkers
  • Accuracy of 80% (+/- 1%) for objectively diagnosing subjects with PTSD
  • Medibio has exclusive worldwide rights to commercialise the technology

SYDNEY, Australia and MINNEAPOLIS, June 26, 2017 (GLOBE NEWSWIRE) -- Australian Stock Exchange-listed medical technology company Medibio Limited (MEB or the Company) announces a new research study, conducted at Emory University, Atlanta GA and funded by Medibio, demonstrates that post-traumatic stress disorder (PTSD) can be accurately diagnosed using a non-invasive protocol involving heart rate data and machine learning algorithms. The research was based on technology developed at Emory University and licensed by Medibio.

The research is described in a paper titled "Classification of post-traumatic stress disorder from heart rate variability metrics with heart rate-based window segmentation," published in the June issue of  P hysiological Measurement .  Emory researchers Gari Clifford, DPhil, MSc, MA, and Amit Shah, MD, MSCR, achieved an accuracy of 80% (+/- 1%) for objectively diagnosing subjects with PTSD and differentiating them from those without PTSD using 24-hour heart rate data and machine learning algorithms.

The researchers noted that,  "O ur results suggest the potential for a non-invasive tool to objectively track PTSD status."

Medibio's collaboration with Emory was announced in January 2017 and is aimed at expanding the use of the technology beyond depression to classifying post-traumatic stress disorder. Under a license agreement, Medibio has the exclusive option and worldwide rights to commercialise new discoveries based on the PTSD diagnostic and monitoring technology developed by Clifford and Shah. The license agreement extends and further solidifies Medibio's intellectual property position and enables the company to service the vast veterans affairs and military clinical markets.

The research was conducted in collaboration with the Department of Veterans Affairs, using its twins database. It is part of a broader ongoing initiative between Emory University and Medibio. A full copy of the paper will be made available on Medibio's website.

Emory's approach used features extracted from quiescent segments, or periods with lowest heart rate (HR), rather than features calculated from the entire 24 hours of ECG heart rate data. The paper states that "Overall, these findings underscore physiologic changes that occur with PTSD, particularly during periods of relative HR quiescence."

The paper concludes that "Our approach of estimating PTSD status from Heart Rate Variability features is non-invasive, automatic, objective, and potentially useful for monitoring progression and/or improvement of a condition".  It suggests that  "future studies could evaluate if this classifier reflects changes with effective treatment and resolution of PTSD."

"We appreciate the research done by Emory University and our collaboration.  The findings from this research provide a significant step forward in assisting veterans by identifying and diagnosing PTSD.  This technology will also assist in the direct benefit for screening, diagnosing and treating mental illness among active military service personnel.  We look forward to future research and commercial activity in the critical areas of veterans mental health diagnosis and management," said Jack Cosentino, Medibio CEO.  "In the United States, over 22 veterans a day commit suicide due to PTSD and mental illness.  This technology will change the way care is delivered to millions of people around the world."

About PTSD
PTSD is a chronic disabling psychiatric condition, with prevalence rates of 3.5% in the general US population(1) and 11-30% amongst returning US service members(2). The disorder represents a significant and costly illness to veterans, their families, and society.  The US Congressional Budget Office has reported that the annual cost of treating a veteran with PTSD is US$8,300. There are 18.8 million veterans in the US including 2.3 million troops deployed in Iraq and Afghanistan over the past 10 years.

Principal researchers
Dr. Gari Clifford, DPhil, MSc, MA, has an international reputation in mHealth and critical care data analysis and the application of signal processing and machine learning to medicine. He joined the faculty at Emory and Georgia Tech in 2014 as an associate professor in the departments of Biomedical Engineering and Bioinformatics, where he is now the interim chair. Previously, as an Associate Professor at the University of Oxford, Dr. Clifford helped found and led one of the five themes at its Sleep & Circadian Neuroscience Institute, where he is now an Honorary Professor. Prior to that, Dr. Clifford was a Principal Research Scientist at MIT, where he managed the collection and dissemination for the world's largest open access hospital database. His research interests focus on machine learning and signal processing for data fusion, prediction and developing confidence intervals and trust metrics. Application areas in health: critical care, mHealth, sleep and circadian rhythms, and resource-constrained environments.

Dr. Amit Shah, MD, MSCR, is an Assistant Professor of Epidemiology with an adjunct appointment in Medicine (Cardiology) at Emory University, and a practicing cardiologist. He is an expert in the study of autonomic function and psychological risk factors for heart disease, and much of his research focuses on understanding the cardiovascular pathophysiology of depression and posttraumatic stress disorder. His training has largely been dedicated to studying the psychophysiology of PTSD, including circadian abnormalities associated with the condition. Recently, his work on PTSD and abnormal circadian rhythm was presented at the American Psychosomatic Society conference.

Disclosure: As inventors and licensees, Drs. Clifford and Shah and Emory University are eligible to benefit financially from this technology. This relationship has been reviewed and is managed by Emory University through its Conflict of Interest office.

About Medibio Limited
Medibio (ASX:MEB) (OTCQB:MDBIF), headquartered in Melbourne, Australia, with US headquarters in Minneapolis, Minnesota, is an evidence-based medical technology company that has developed an objective test to assist in the diagnosis and management of depression, chronic stress and other mental health disorders. Based on research conducted over 15 years at the University of Western Australia, this test utilizes a panel of patented (and patent pending) circadian, sleep and autonomic system biomarkers to objectively quantify and characterize mental state.  Medibio's depression diagnostic is being validated in clinical studies undertaken by Johns Hopkins University School of Medicine and The University of Ottawa, among others. The clinical trials will support Medibio's application to become the first FDA approved, objective, and evidence based approach to the diagnosis of mental health disorders. Medibio's technology also provides an objective method for the assessment of stress and mental wellbeing that can be translated to the workplace stress/wellbeing market, wearable technology and App market. Medibio is listed on the Australian Securities Exchange. and also trades on the OTCQB Venture Market for early stage and developing U.S. and international companies. Investors can find Real-Time quotes and market information for the company on www.otcmarkets.com and www. asx.com.au.

To learn more about Medibio visit www.Medibio.com.au 

(1) http://www.nimh.nih.gov/health/statistics/prevalence/post-traumatic-stress-disorder-among-adults.shtml (2) http://www.ptsd.va.gov/public/PTSD-overview/basics/how-common-is-ptsd.asp

Further Information: Website: www.medibio.com.au
Medibio Shareholder Enquiries:
Jack Cosentino
CEO and Managing Director
Medibio Limited
jack.cosentino@medibio.com.au
T: +1 (952) 465 4787
  U.S. Media Enquiries:
Nancy Thompson
Vorticom Inc.
nancyt@vorticom.com
T: +1 (212) 532 2208
  Australian Media Enquiries:
Peter Taylor
NWR Communications
peter@nwrcommunications.com.au
T: +61 (0) 412 036 231




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Medibio Limited via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

PayByPhone appoints Andreas Gruber as new President and CEO20.4.2018 00:19Pressmeddelande

VANCOUVER, British Columbia, April 19, 2018 (GLOBE NEWSWIRE) -- PayByPhone, the global leader in mobile parking payments, today announced that it will appoint Andreas Gruber as president and Chief Executive Officer effective June 1st, 2018. Francis Dupuis, the former President and CEO, will take over a position in Germany with parent company Volkswagen Financial Services AG. To provide additional impetus to the PayByPhone board, two new board positions have been created and as a result Maggie Clay (CFO) and Catherine Scott (Legal Counsel) will be appointed effective June 1st, 2018. During his time at PayByPhone, Francis led the business through significant growth and organizational change and leaves the company well positioned for continued success. "We would like to thank Francis for his strong leadership and look forward to building on his experience within Volkswagen Financial Services," Gerd Künne, Vice-President of mobility unit at Volkswagen Financial Services, said. Francis is e

Progress and Potential for Achieving Cleaner Air on a Global Basis20.4.2018 00:09Pressmeddelande

Adoption of New Generation Diesel Technology Delivers Rapid Clean Air Benefits New understanding of global air quality highlights the need for technologies like new-generation diesel engines, which are capable of accelerating emissions reductions WASHINGTON, April 19, 2018 (GLOBE NEWSWIRE) -- Recent reports highlighting air quality conditions in the United States (State of the Air) and globally (State of Global Air 2018) celebrate the progress made in developed and developing countries, but also emphasize significant disparities in progress toward reducing levels of key pollutants such as particulate matter and ozone. "Achieving continued clean air progress while also sustaining economic growth is possible. Cities and countries must move to proven cleaner engines and fuels," said Allen Schaeffer, executive director of the Diesel Technology Forum. "We can and should bring the tremendous benefits of new technology diesel engines to communities and countries large and small around the wor

SD-WAN for Office 365: Aryaka Helps eLearning company, City & Guilds Group, Improve Office 365 Application Response Time19.4.2018 18:54Pressmeddelande

Aryaka's Global SD-WAN reduces time for global users to open SharePoint files from 10 to 0.05 seconds; Outlook performance improves 9x worldwide LONDON, April 19, 2018 (GLOBE NEWSWIRE) -- Aryaka®, the leading global SD-WAN provider, announced today its SD-WAN technology has enabled City & Guilds Group, a worldwide leader in workplace skills, eLearning, and executive coaching, to achieve faster Office 365 application response times leading to an increase in productivity and better collaboration between users in Europe and Asia-Pacific. Headquartered in London, the City & Guilds Group works with education providers, governments and major corporations to help shape and support skills development for employers in over 100 countries. Team members of the company are similarly scattered around the world and primarily collaborate using Microsoft Office 365 applications, but many remote users were struggling to access the group's instance of Office 365 hosted in Dublin. For example, it could ta

Canacol Energy Ltd. Announces Private Offering of Senior Notes19.4.2018 16:23Pressmeddelande

CALGARY, Alberta, April 19, 2018 (GLOBE NEWSWIRE) -- Canacol Energy Ltd. ("Canacol" or the "Corporation") (TSX:CNE) (OTCQX:CNNEF) (BVC:CNEC) is pleased to announce that it intends, subject to market and other conditions, to offer senior unsecured notes (the "Notes") in a private placement to qualified institutional buyers in the United States pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"), to non-U.S. persons in transactions outside the United States pursuant to Regulation S under the Securities Act and pursuant to certain prospectus exemptions in Canada (the "Offering"). The Notes will be fully and unconditionally guaranteed by certain subsidiaries of Canacol. The interest rate, redemption prices and other terms of the Notes are to be determined upon pricing of the Offering. Canacol intends to use the net proceeds from the Offering: (i) to repay the outstanding amounts borrowed under its credit facility; (ii) to pay fees and expenses of the O

FinancialForce Extends Professional Services Automation Leadership With its Spring 2018 Release19.4.2018 14:00Pressmeddelande

New features empower services organizations to run their businesses with greater predictability, assign best-fit resources at scale, and forecast projects with 360-degree insight. SAN FRANCISCO, April 19, 2018 (GLOBE NEWSWIRE) -- FinancialForce, the number one customer-centric ERP cloud vendor built on the Salesforce Platform, announced the availability of its latest version of Professional Services Automation, the highest customer-rated PSA solution for enterprise organizations. The Spring 2018 Release of PSA brings new functional capabilities to accelerate project staffing speed and accuracy; unify people and project data; enable better forecasting decisions; and enhance the overall user experience using the Salesforce Lightning framework. Fast, Accurate Resource Mapping With the Spring 2018 Release of PSA, project and resource managers can identify and assign best-fit resources with greater speed and accuracy. Through advanced skills filtering and search capabilities, including part

SpeeDx receives FDA clearance for Mycoplasma genitalium product19.4.2018 14:00Pressmeddelande

SYDNEY, Australia, April 19, 2018 (GLOBE NEWSWIRE) -- SpeeDx's Resistance Plus ® MG Positive Control kit has now been listed with the US Food and Drug Administration (FDA) for sale in the United States through the company's recently incorporated US entity, SpeeDx Inc. The announcement coincides with the FDA registration of the Australian parent company - SpeeDx Pty Ltd - as a Medical Device Manufacturing Establishment, and clinical trials remain on-track for the Resistance Plus MG assay.* The Resistance Plus MG Positive Control kit contains synthetic DNA to simulate Mycoplasma genitalium, as well as five mutations known to confer resistance to macrolide antibiotics. Macrolide-resistant M. genitalium is a challenging sexually transmitted infection (STI), and global management guidelines are currently being adapted to deal with the rise in resistance. "This is an important product in our portfolio," said Elisa Mokany, Chief Technology Officer for SpeeDx. "M. genitalium is very difficult

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum